An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Takeda draws a cautious line under Iclusig
$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Iclusig comes too late to rescue Takeda
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
